摘要
Abstract
Hodgkin lymphoma (HL) is the first hematolymphoid malignancy proven to be curable with multi-agent combination chemotherapy. Current first-line treatment achieves complete remission in more than 80％ of patients;however,20％ of advanced cases are refractory to standard regimens or relapse after treatment,with even poorer prognosis in newly diagnosed refractory patients.In recent years,the tumor microenvironment(TME)has been increasingly recognized as playing a critical role in the occurrence,progression,treatment,and prognosis of HL.The TME of HL is enriched with immune cells such as T lymphocytes,tumor-associated macrophages,myeloid-derived suppressor cells,tumor-associated fibroblasts,and other cellular components,all of which promote tumor development.Targeted drugs developed against immune cells within the TME,such as nivolumab,pembrolizumab,brentuximab vedotin,and phosphatidylinositol 3-kinase(PI3K)δ/γ inhibitors,have emerged as new therapeutic options for HL.The TME represents both the origin and survival niche of HL cells.Elucidating the mechanisms of TME-mediated immune evasion and related targeted therapeutic strategies is of great importance for guiding clinical applications.关键词
霍奇金淋巴瘤/肿瘤微环境/免疫逃逸/免疫细胞/靶向治疗Key words
Hodgkin lymphoma/tumour microenvironment/immune evasion/immune cells/targeted therapy
